CLINICAL TRIALS PROFILE FOR PENICILLAMINE

All Clinical Trials for Penicillamine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003751 ↗	Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma	Completed	National Cancer Institute (NCI)	Phase 2	1999-03-01	RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00003751 ↗	Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	1999-03-01	RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00003751 ↗	Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	1999-03-01	RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.
NCT00161148 ↗	Probiotics in Patients With Primary Sclerosing Cholangitis	Unknown status	UMC Utrecht	Phase 3	2005-01-01	PSC is a progressive liver disease without effective medical treatment. There is often co-existent ulcerative colitis. Probiotics (bacterial food supplements) have been shown to benefit patients with ulcerative colitis. In the current protocol potential beneficial effects of probiotics on liver biochemistry and liver related symptoms as pruritus are being assessed in 12 PSC patients in a randomized controlled cross over study (3 months probiotics, 1 one wash-out and 3 months placebo).

Clinical Trial Conditions for Penicillamine

Condition Name

Condition Name for Penicillamine
Intervention	Trials
Wilson Disease	4
Scleroderma	2
Wilson's Disease	2
Rheumatoid Arthritis	1

Condition MeSH

Condition MeSH for Penicillamine
Intervention	Trials
Hepatolenticular Degeneration	6
Arthritis, Rheumatoid	2
Scleroderma, Diffuse	2
Arthritis	2

Clinical Trial Locations for Penicillamine

Trials by Country

Trials by Country for Penicillamine
Location	Trials
United States	31
United Kingdom	4
China	3
Poland	3
Germany	3

Trials by US State

Trials by US State for Penicillamine
Location	Trials
Connecticut	3
Texas	3
Pennsylvania	3
Michigan	2
Massachusetts	2

Clinical Trial Progress for Penicillamine

Clinical Trial Phase

Clinical Trial Phase for Penicillamine
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Penicillamine
Clinical Trial Phase	Trials
Completed	9
Active, not recruiting	2
Unknown status	2

Clinical Trial Sponsors for Penicillamine

Sponsor Name

Sponsor Name for Penicillamine
Sponsor	Trials
FDA Office of Orphan Products Development	1
GMP-Orphan SAS	1
Gilead Sciences	1

Sponsor Type

Sponsor Type for Penicillamine
Sponsor	Trials
Industry	12
Other	11
NIH	2